Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...
The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
Biotech stock GeneDx broke out after the FDA issued its first AI rules for medical devices. Globus Medical and GeneDx are in ...
The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized myasthenia gravis who are antibody positive, according to the manufacturer.
Opponents argue that the change could cause current smokers to use more cigarettes to compensate for the lower nicotine ...
Years of research have showed that pulse oximeters yield less accurate readings for people with darker skin tones, and now ...
The FDA has set maximum levels for lead in baby food. A new California law requires baby food makers selling products in the ...
The recalled "Connie's Thin Crust Cheese Pizza" was issued a Class II risk level by the FDA, the second-most severe risk ...
D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...